172@29@17@240!~!172@29@0@53!~!|news|business|lupin-gets-usfda-nod-for-generic-diabetes-drug-5644151.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
you are here: HomeNewsBusiness
Last Updated : Aug 04, 2020 04:22 PM IST | Source: PTI

Lupin gets USFDA nod for generic diabetes drug

The Mumbai-based company has received a tentative approval from the US Food and Drug Administration (USFDA) for its Empagliflozin tablets, in strengths of 10 mg and 25 mg, Lupin said in a statement.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug maker Lupin on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in America.

The Mumbai-based company has received a tentative approval from the US Food and Drug Administration (USFDA) for its Empagliflozin tablets, in strengths of 10 mg and 25 mg, Lupin said in a statement.

The product is a generic version of Boehringer Ingelheim Pharmaceuticals, Inc's Jardiance tablets which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Close
As per IQVIA MAT March 2020 data, the drug had an annual sales of around $4,368 million in the US.
First Published on Aug 4, 2020 04:15 pm
Sections